This company has been marked as potentially delisted and may not be actively trading. NYSE:GLS Gelesis (GLS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Gelesis Stock (NYSE:GLS) 30 days 90 days 365 days Advanced Chart Get Gelesis alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.11▼$0.3352-Week Range N/AVolume185,100 shsAverage Volume386,034 shsMarket Capitalization$11.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts. Read More Receive GLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gelesis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLS Stock News HeadlinesGelesis Holdings Inc GLSHQDecember 9, 2023 | morningstar.comMNYSE to suspend trading immediately in Gelesis HoldingsApril 11, 2023 | msn.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.September 15 at 2:00 AM | Porter & Company (Ad)NYSE to Suspend Trading Immediately in Gelesis Holdings, Inc. (GLS) and Commence Delisting ProceedingsApril 10, 2023 | finance.yahoo.comLooking Into Gelesis Holdings's Return On Capital EmployedMarch 29, 2023 | msn.comGelesis Reports Fourth Quarter and Full Year 2022 ResultsMarch 28, 2023 | finance.yahoo.comGLS Gelesis Holdings, Inc.January 27, 2023 | seekingalpha.comGelesis to Participate in the 25th Annual ICR ConferenceJanuary 5, 2023 | finance.yahoo.comSee More Headlines GLS Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Gelesis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gelesis investors own include VIQ Solutions (VQS), Faraday Future Intelligent Electric (FFIE), Eos Energy Enterprises (EOSE), Danimer Scientific (DNMR), Crown ElectroKinetics (CRKN), Boxed (BOXD) and BitNile Metaverse (BNMV). Company Calendar Today9/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:GLS CIK1805087 Webwww.gelesis.com PhoneN/AFaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$56.03 million Net Margins-221.38% Pretax Margin-214.62% Return on EquityN/A Return on Assets-14.98% Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.21 Sales & Book Value Annual Sales$25.77 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.34) per share Price / BookN/AMiscellaneous Outstanding Shares73,333,000Free Float64,606,000Market Cap$11.63 million OptionableNot Optionable Beta0.88 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NYSE:GLS) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelesis Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
